Most coverage of compounded semaglutide is still arguing about 2025 — whether the shortage really ended, whether the compounders were treated fairly, whether the copies were as good. That argument is settled in the regulatory record and the search volume for it has fallen by roughly two thirds year on year. The more useful question in 2026 is what is arriving in its place, and the answer is sitting in two FDA databases that almost nobody queries. This page reports what they contain. It is journalism about a regulatory record and does not tell anyone what to take; that belongs with a clinician, as our editorial standards say.
The legal position, in one query
Compounding a drug that is essentially a copy of an approved product is permitted in the United States only while that product sits on FDA's shortage list. That is the entire mechanism, and it means the legal question has a database answer.
Searched on openFDA's drug shortages endpoint, 2026-09-07: semaglutide injection returns no records. Not a resolved record, not a historical entry — no row. Tirzepatide returns none either.
The dates behind that absence: semaglutide's shortage was declared resolved on 2025-02-21, and FDA's enforcement discretion ended on 2025-04-22 for 503A pharmacies and 2025-05-22 for 503B outsourcing facilities. The mechanics of how those determinations work, the litigation around them, and what FDA has documented about the compounded products themselves — dosing errors, unapproved salt forms, counterfeit labelling and three waves of warning letters — are set out on our compounded tirzepatide page, which covers the same law from the other drug's side. This page does not repeat them.
One correction to the way this is usually described, from the same database in the same session: the class did not leave the shortage list together. Liraglutide injection carries five current shortage entries today. "The GLP-1 shortage" was never a single event; it was a set of product-by-product supply determinations with separate dates, and one of them is still open.
What is actually replacing it: a generic, already approved
Here is the finding that consumer coverage of this subject has not caught up with.
Apotex holds a tentative approval for generic semaglutide injection. ANDA 220314, granted 2026-04-07, covering three strengths:
| Strength | Status |
|---|---|
| 2 mg/3 mL | Tentative approval |
| 4 mg/3 mL | Tentative approval |
| 8 mg/3 mL | Tentative approval |
Source: openFDA Drugs@FDA, application ANDA 220314, read 2026-09-07.
A tentative approval is widely misread, so it is worth being exact. It does not mean FDA has doubts about the product. It means the opposite: FDA has reviewed the application and concluded that it meets every standard required for approval — manufacturing quality, bioequivalence, labelling — and that the product cannot be marketed yet only because patent or exclusivity protection on the brand has not expired. The scientific and regulatory work is finished. What remains is a legal clock.
That matters for anyone reasoning about this market, because it changes the shape of the future. The compounded product existed to fill a gap between demand and an expensive, supply-constrained brand. The thing that closes that gap durably is not a compounder; it is a generic, and a generic is now through the review process and waiting.
This page will not predict when it launches. Patent expiry and exclusivity litigation are not publicly resolvable to a date, and a page that guessed one would be making up the most important number on it.
The oral product line is being renamed
The second finding from the same session, and a genuinely current one: Rybelsus is being discontinued.
FDA's shortage database carries a notice dated 2026-06-04 covering all three Rybelsus tablet strengths — 3 mg, 7 mg and 14 mg — with the status "To Be Discontinued" and this stated reason:
Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.
The replacement is already visible in the approval file. NDA 213051 — the application Rybelsus was approved under in 2019 — now carries Ozempic tablets at 1.5 mg, 4 mg and 9 mg, alongside the Rybelsus tablets at 3 mg, 7 mg and 14 mg. All six are listed as prescription products.
So this is a rebranding with new strengths inside one product family, not a withdrawal of oral semaglutide. Read together with the separate approval of Wegovy tablets under NDA 218316 in December 2025, which our GLP-1 pills page prices dose by dose, the direction is clear enough: Novo is consolidating oral semaglutide under its two strongest brand names and retiring the third.
Why this is the more useful frame
The compounded-semaglutide question is usually posed as a moral one — was the copy legitimate, were patients abandoned, was FDA captured. Those arguments are available in quantity elsewhere and this publication has no standing to settle them.
What a person actually deciding something needs is narrower and more boring:
- Routine compounded copies lost their legal basis in 2025 and the shortage record that permitted them no longer exists.
- The approved products are available, and their self-pay prices are not what they were in 2023.
- A generic injection has cleared FDA review and is waiting on patents, which is the mechanism that historically ends this kind of price gap for good.
- The oral line is being renamed, not removed, so a Rybelsus prescription running out is a supply change rather than a treatment ending.
Every one of those is checkable in two public databases in under a minute, which is the only reason this page can state them plainly.
Sources and dates
All records read 2026-09-07. Generic status: openFDA Drugs@FDA, ANDA 220314 (Apotex), tentative approval dated 2026-04-07. Rybelsus discontinuation and the liraglutide entries: openFDA drug shortages endpoint. Ozempic tablet strengths: openFDA Drugs@FDA, NDA 213051. Shortage-resolution and enforcement-discretion dates for semaglutide, and the FDA documentation of compounded-product problems, are sourced on our compounded tirzepatide page, read 2026-09-05.